Insiders · ALNY

Phillip A Sharp

Director at Alnylam Pharmaceuticals, Inc. (ALNY)

Phillip A Sharp has filed 13 insider reports with the SEC since May 2021, as director at Alnylam Pharmaceuticals, Inc. (ALNY), director at Vir Biotechnology, Inc. (VIR) and director at Syros Pharmaceuticals, Inc. (SYRS). Phillip A Sharp made no open-market purchases or sales in the last 12 months. In the latest filing, on January 24, 2025, Phillip A Sharp sold 11,250 shares of Alnylam Pharmaceuticals, Inc. (ALNY) for $3.09M at an average of $275.00.

Filings
13
Companies
3
Bought on market
None
Sold on market
$15.4M

Companies where Phillip A Sharp is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Alnylam Pharmaceuticals, Inc. logo
ALNY
Alnylam Pharmaceuticals, Inc.
Director0$15.4M$147.82Jan 24, 2025
Vir Biotechnology, Inc. logo
VIR
Vir Biotechnology, Inc.
Director121,174$8.87Jul 10, 2024
Syros Pharmaceuticals, Inc. logo
SYRS
Syros Pharmaceuticals, Inc.
DirectorJun 2, 2022

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Also sits on boards with

Officers and directors who share two or more companies with Phillip A Sharp.

Compare Phillip A Sharp with

Other insiders at the same companies

Questions about Phillip A Sharp

What is Phillip A Sharp's role at Alnylam Pharmaceuticals, Inc.?
Phillip A Sharp reports to the SEC as director at Alnylam Pharmaceuticals, Inc. (ALNY), according to the latest filing on January 24, 2025. Phillip A Sharp has also filed as director at Vir Biotechnology, Inc. (VIR) and director at Syros Pharmaceuticals, Inc. (SYRS).
How many shares does Phillip A Sharp own?
After the latest filing that states it, Phillip A Sharp directly owned 121,174 shares of Vir Biotechnology, Inc. (VIR). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Phillip A Sharp bought or sold stock recently?
The most recent open-market sale was on January 23, 2025: sold 11,250 shares of Alnylam Pharmaceuticals, Inc. (ALNY) for $3.09M at an average of $275.00.
How do I get alerts when Phillip A Sharp files?
Follow Phillip A Sharp on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Phillip A Sharp (SEC CIK 0001226295). Totals count each trade once, skipping amendments whose original is on file, from May 25, 2021 on. View on SEC EDGAR · Get this as JSON